Have a feature idea you'd love to see implemented?
Let us know!
NPCE NeuroPace Inc
Price (delayed)
$5.925
Market cap
$172.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.08
Enterprise value
$233.69M
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating
Highlights
NeuroPace's gross profit has increased by 36% YoY and by 4.2% from the previous quarter
NeuroPace's EPS has increased by 36% YoY and by 8% QoQ
NPCE's equity has dropped by 53% year-on-year and by 31% since the previous quarter
NeuroPace's quick ratio has decreased by 18% YoY
Key stats
What are the main financial stats of NPCE
Market
Valuations
Earnings
Shares outstanding
29.2M
Market cap
$172.99M
Enterprise value
$233.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
17.24
Price to sales (P/S)
2.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.25
Revenue
$71.82M
EBIT
-$21.05M
EBITDA
-$19.37M
Free cash flow
-$17.28M
Per share
Balance sheet
Liquidity
EPS
-$1.08
Free cash flow per share
-$0.6
Book value per share
$0.34
Revenue per share
$2.49
TBVPS
$3.27
Total assets
$94.39M
Total liabilities
$84.5M
Debt
$73.66M
Equity
$9.89M
Working capital
$67.64M
Debt to equity
7.45
Current ratio
6.37
Quick ratio
5.32
Net debt/EBITDA
-3.13
Margins
Efficiency
Dividend
EBITDA margin
-27%
Gross margin
74.2%
Net margin
-41.6%
Operating margin
-34.5%
Return on assets
-29.9%
Return on equity
-195.3%
Return on invested capital
-14.5%
Return on capital employed
-25.7%
Return on sales
-29.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NPCE stock price
How has the NeuroPace stock price performed over time
Intraday
-1.25%
1 week
-8%
1 month
-17.94%
1 year
-9.13%
YTD
-42.53%
QTD
-14.99%
Financial performance
How have NeuroPace's revenue and profit performed over time
Revenue
$71.82M
Gross profit
$53.26M
Operating income
-$24.78M
Net income
-$29.9M
Gross margin
74.2%
Net margin
-41.6%
NeuroPace's operating margin has increased by 48% YoY and by 10% from the previous quarter
The net margin has increased by 46% YoY and by 9% from the previous quarter
NeuroPace's gross profit has increased by 36% YoY and by 4.2% from the previous quarter
The operating income has increased by 32% year-on-year and by 6% since the previous quarter
Growth
What is NeuroPace's growth rate over time
Valuation
What is NeuroPace stock price valuation
P/E
N/A
P/B
17.24
P/S
2.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.25
NeuroPace's EPS has increased by 36% YoY and by 8% QoQ
NPCE's equity has dropped by 53% year-on-year and by 31% since the previous quarter
The price to book (P/B) is 9% lower than the last 4 quarters average of 19.1
NPCE's price to sales (P/S) is 43% less than its last 4 quarters average of 4.2
NPCE's revenue is up by 31% year-on-year and by 4% since the previous quarter
Efficiency
How efficient is NeuroPace business performance
NeuroPace's return on sales has surged by 53% YoY and by 11% QoQ
NeuroPace's ROE has decreased by 46% YoY and by 13% from the previous quarter
NPCE's ROIC is up by 31% year-on-year and by 5% since the previous quarter
The company's return on assets rose by 22% YoY and by 3.2% QoQ
Dividends
What is NPCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NPCE.
Financial health
How did NeuroPace financials performed over time
NPCE's total assets is 12% higher than its total liabilities
NeuroPace's quick ratio has decreased by 18% YoY
The company's current ratio fell by 15% YoY
NeuroPace's debt to equity has surged by 122% YoY and by 46% QoQ
NPCE's equity has dropped by 53% year-on-year and by 31% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.